Ó³»­´«Ã½

Tom Miller, Ph.D., is a scientist and entrepreneur with a focus on the nexus of AI, chemistry and biology. Since 2020, he has served as Co-founder and Chief Executive Officer of Iambic Therapeutics, a clinical-stage biotechnology company that is disrupting the therapeutics landscape with a unique, AI-driven, drug-discovery platform. Prior to this, he served over 10 years as a professor at the California Institute of Technology (Caltech), receiving tenure, publishing over 140 peer-reviewed articles and patents, and receiving numerous awards for research and entrepreneurial excellence. Dr. Miller earned a B.S. in Chemistry and Mathematics from Texas A&M University and a Ph.D. in Theoretical Chemistry from the University of Oxford.

Iambic Therapeutics has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated drugs. The Iambic platform has been demonstrated to deliver best-in-class and first-in-class development candidates to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Today, the Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs, with particular focus on breast, lung, and brain cancers. Its lead program, a highly selective HER2 inhibitor for the treatment of solid tumors, entered Phase 1 clinical studies in Q1 2024.